Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence

Pediatr Pulmonol. 2014 May;49(5):503-7. doi: 10.1002/ppul.22937. Epub 2013 Oct 25.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti-IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti-IgE resulting in improved FEV1 , fewer respiratory symptoms and decreased corticosteroid use.

Keywords: A. fumigatus; ABPA; anti-IgE.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anti-Allergic Agents / therapeutic use*
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Aspergillosis, Allergic Bronchopulmonary / complications
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Child
  • Cystic Fibrosis / complications*
  • Female
  • Humans
  • Male
  • Omalizumab
  • Treatment Outcome

Substances

  • Anti-Allergic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Omalizumab